8-K: TNF Pharma Closes $7M Private Placement at Premium

TNF Pharmaceuticals closes a $7M private placement financing led by a strategic investor at a 44% premium to market.

Summary

• TNF Pharmaceuticals closed a $7.0 million private placement financing.
• The financing involved the sale of 7,000 shares of convertible preferred stock with a stated value of $1,000 per share.
• The preferred stock is convertible into 1,400,000 shares of common stock at an initial conversion price of $5.00.
• Accompanying warrants were issued to purchase up to 1,400,000 shares of common stock at an exercise price of $5.00.
• The private placement was led by the company's largest strategic stockholder with significant participation from existing stockholders.
• As of September 3, 2025, TNFs shares of common stock outstanding totaled 1,846,930.

Sentiment

Score: 8

Explanation: The announcement is generally positive, highlighting a successful capital raise at a premium and strategic investor confidence. However, risks and uncertainties are also acknowledged.

Positives

• The private placement was priced at a 44% premium to market.
• The financing was led by a top strategic investor, indicating confidence in the company.
• The $7 million in new capital will position TNF to complete key development milestones for its newly licensed innovative technology.
• The company is actively engaging strategic opportunities to continue the development of isomyosamine and Supera-CBD.

Negatives

• The shares of preferred stock and warrants will not be convertible or exercisable, respectively, until receipt of the requisite stockholder approval.

Risks

• Unanticipated financial setbacks.
• The Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions.
• The Companys ability to maintain compliance with the Nasdaq Stock Markets listing standards.
• The timing of, and the Companys ability to, obtain and maintain regulatory approvals for clinical trials of the Companys pharmaceutical candidates.
• The timing and results of the Companys planned clinical trials for its pharmaceutical candidates.
• The amount of funds the Company requires for its pharmaceutical candidates.
• Increased levels of competition.
• Changes in political, economic or regulatory conditions generally and in the markets in which the Company operates.
• The Companys ability to retain and attract senior management and other key employees.
• The Companys ability to quickly and effectively respond to new technological developments.
• The Companys ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Companys proprietary rights.

Future Outlook

The company believes the $7 million in new capital positions TNF to complete key development milestones planned for its newly licensed innovative technology, which it believes is the first light-based computing accelerator for blockchain. The company is actively engaging strategic opportunities to continue the development of isomyosamine and Supera-CBD, with the goal of ensuring these assets continue to create value for shareholders.

Management Comments

• "We appreciate the vote of confidence in TNFs value proposition and execution of our newest strategies," said Joshua Silverman, TNFs Executive Chairman.
• "We believe the $7 million in new capital positions TNF to complete key development milestones planned for our newly licensed innovative technology, which we believe is the first light-based computing accelerator for blockchain."
• "We are actively engaging strategic opportunities to continue the development of isomyosamine and Supera-CBD," said Mitchell Glass, Chief Medical Officer.
• "Our goal is to ensure these assets continue to create value for shareholders."

Industry Context

The company is focusing on innovative technology, specifically a light-based computing accelerator for blockchain, which is a growing area of interest in the technology and pharmaceutical industries. The company is also continuing the development of isomyosamine and Supera-CBD, which are related to the pharmaceutical industry.

Comparison to Industry Standards

• It is difficult to compare this private placement to industry standards without knowing the specific terms and conditions of the offering, as well as the company's financial performance and future prospects.
• However, the fact that the private placement was priced at a 44% premium to market suggests that investors have confidence in the company's future prospects.
• It is also worth noting that the private placement was led by a top strategic investor, which could provide the company with valuable expertise and resources.

Stakeholder Impact

• Shareholders: Positive impact due to new capital and strategic investor confidence.
• Employees: Positive impact due to funding for key development milestones.
• Customers: Potential positive impact due to development of new technologies and products.

Next Steps

• Complete key development milestones planned for the newly licensed innovative technology.
• Actively engage strategic opportunities to continue the development of isomyosamine and Supera-CBD.
• Obtain the requisite stockholder approval for the conversion of the preferred stock and the exercise of the warrants.

Key Dates

Recommendation

The successful private placement at a premium, led by a strategic investor, suggests strong confidence in the company's future prospects. The new capital will enable the company to achieve key development milestones and continue the development of its innovative technologies. While risks and uncertainties exist, the potential upside appears to outweigh the downside, making it a buy recommendation.

Keywords

private placement, convertible preferred stock, warrants, financing, capital raise, TNF Pharmaceuticals, TNFA, isomyosamine, Supera-CBD, blockchain